This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin. (MSD-GLP1)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
The Royal Bournemouth Hospital Identifier:
First received: September 4, 2008
Last updated: December 4, 2012
Last verified: September 2008
The study is aimed at Type 2 Diabetics who are taking Metformin, but whose Diabetes remains poorly controlled. There are two additional medications already in use, Glimepiride and Sitagliptin will be compared to assess levels of improvement in Diabetes control.

Condition Intervention
Type 2 Diabetes Mellitus Drug: Glimepiride Drug: Sitagliptin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition.

Resource links provided by NLM:

Further study details as provided by The Royal Bournemouth Hospital:

Primary Outcome Measures:
  • Comparison of GLP-1 response at baseline and after 3 months treatment of both groups. [ Time Frame: 2 years ]

Enrollment: 74
Study Start Date: September 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Glimepiride
3mg oral tablet.
Other Name: Amaryl.
Active Comparator: 2 Drug: Sitagliptin
100mg oral tablet.
Other Name: Januvia.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes Mellitus
  • Currently on Metformin but poor glycaemic control,

Exclusion Criteria:

  • Under 18 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00747383

United Kingdom
Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom, BH7 7DW
Sponsors and Collaborators
The Royal Bournemouth Hospital
Merck Sharp & Dohme Corp.
Principal Investigator: David Kerr Royal Bournemouth Hospital
Principal Investigator: Joseph Begley Royal Bournemouth Hospital
  More Information

Responsible Party: The Royal Bournemouth Hospital Identifier: NCT00747383     History of Changes
Other Study ID Numbers: 08/H0201/57
Study First Received: September 4, 2008
Last Updated: December 4, 2012

Keywords provided by The Royal Bournemouth Hospital:
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sitagliptin Phosphate
Glucagon-Like Peptide 1
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents
Immunosuppressive Agents
Immunologic Factors processed this record on September 20, 2017